Form 4: Major Shareholder Atomico Sells Over 2.6 Million Hinge Health Shares Following Conversion

Atomico Advisors IV, Ltd., a 10% owner and director of Hinge Health, Inc., sold 2,651,103 shares of Class A Common Stock at $32 per share after converting them from Class B Common Stock.

Summary

• Atomico Advisors IV, Ltd., along with its related entities Atomico IV, L.P. and Atomico IV (Guernsey), L.P., reported significant transactions in Hinge Health, Inc. (HNGE) securities.
• On May 23, 2025, the reporting persons converted 2,651,103 shares of Class B Common Stock into an equal number of Class A Common Stock.
• Immediately following this conversion, they disposed of all 2,651,103 shares of Class A Common Stock at a price of $32 per share.
• Prior to these transactions, various series of preferred stock (Series A-2, B, C, C-1, D) held by Atomico were reclassified and converted into Class B Common Stock, totaling 9,364,166 shares of Class B Common Stock.
• After the reported sale, the reporting persons beneficially own 6,713,063 shares of Class B Common Stock indirectly, held by Atomico IV (5,476,823 shares) and Atomico IV (Guernsey) (1,236,240 shares).

Sentiment

Score: 3

Explanation: The sale of a significant block of shares by a major institutional investor and director, even if for portfolio management reasons, is generally viewed with caution by the market as it reduces insider alignment and can signal a perceived ceiling on valuation or a strategic exit.

Positives

• The sale occurred at a specific price of $32 per share, providing a clear valuation for the transaction.

Negatives

• A significant sale of shares (2,651,103 shares) by a 10% owner and director could be perceived negatively by the market, potentially signaling a lack of confidence or a move to realize gains.
• The transaction represents a substantial reduction in the reporting persons' direct Class A Common Stock holdings to zero following the sale.

Risks

• Large insider sales can sometimes lead to negative market sentiment and downward pressure on the stock price.
• The reduction in ownership by a significant institutional investor (Atomico) might raise questions among investors about future strategic alignment or long-term commitment to the company.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports a change in beneficial ownership by an insider.

Industry Context

This Form 4 filing reflects a significant transaction by a venture capital firm (Atomico) that was an early investor in Hinge Health. Such sales are common for venture capital funds as they seek to realize returns on their investments, particularly after an initial public offering (IPO) or a period of significant growth. The digital health and musculoskeletal care market, in which Hinge Health operates, is dynamic, and investor exits are a natural part of the investment lifecycle for early-stage investors.

Management Changes

Stakeholder Impact

• Shareholders may react negatively to the significant sale of shares by a major institutional investor and director, potentially leading to a decrease in stock price due to concerns about insider confidence or future growth prospects.

Next Steps

• The document does not specify any future actions, events, or milestones for Hinge Health, Inc. It only reports past transactions by the reporting persons.

Key Dates

Recommendation

Keywords

Hinge Health, HNGE, SEC Form 4, Insider Trading, Stock Sale, Beneficial Ownership, Atomico, Class A Common Stock, Class B Common Stock, Preferred Stock Conversion, Institutional Investor